Preterm Birth Clues Identified in Cervicovaginal Microbiome
|
By LabMedica International staff writers Posted on 03 Apr 2019 |

Image: The HiSeq 2500 System is a powerful high-throughput sequencing system (Photo courtesy of Illumina).
Failure to predict and understand the causes of preterm birth, the leading cause of neonatal morbidity and mortality, have limited effective interventions and therapeutics. Preterm birth (PTB) is defined as birth before 37 completed weeks of gestation and is the leading cause of death in neonates and children under the age of 5.
The interaction between microbial communities and their host, in many biological niches, has been found to be mechanistically involved in health and disease pathogenesis. There have been only a few studies that have examined the relationship between cervicovaginal microbial communities and spontaneous preterm birth.
A group of scientists collaborating with the University of Maryland School of Medicine (Baltimore, MD, USA) enrolled within 2,000 pregnant women, and identified a few hundred women for a nested case-control study of spontaneous preterm birth (sPTB), a group that included 107 extensively phenotyped women who gave birth prior to 37 weeks of gestation and 432 unaffected women who delivered their babies at term. Nearly three-quarters of the participants were African-American, and the median age of the mothers was 28 years old. The investigators had access to cervicovaginal swab samples and anthropometric measurements collected at three points during pregnancy: at 16 to 20 weeks gestation, 20 to 24 weeks gestation, and between 24 and 28 weeks gestation.
Amplicons were visualized on a 2% agarose gel, quantified, pooled in equimolar concentration, and purified prior to loading on an Illumina HiSeq 2500 modified to generate 300 bp paired-end reads. When the scientists compared microbial community members in cervicovaginal samples from those cases and controls, which were profiled with 16S ribosomal RNA gene sequencing, they saw seven bacterial taxa that appeared to be associated with spontaneous preterm birth, particularly in women with African-American ancestry. The team studied that association further using enzyme-linked immunosorbent assay (ELISA)-based immunological profiling, focused on host-derived anti-microbial peptides known as beta-defensin-2, that have previously been described in studies of the genital tract, both in healthy women and those suffering from bacterial infections.
The results indicated that the presence of Lactobacillus bacteria that are normally considered beneficial did not necessary coincide with diminished risk of spontaneous preterm birth. Instead, the data suggested that enhanced beta-defensin-2 levels in cervicovaginal samples typically coincided with decreased spontaneous preterm birth risk, while lower-than-usual levels of the protein tended to track with increased risk, even when high levels of bacteria belonging to Lactobacillus species were present. That beta-defensin-2 effect was especially pronounced in the African-American women, but was not significant when the team analyzed data for non-African-American women alone. Likewise, African-American women who delivered their infants at term also had increased beta-defensin-2 levels compared to non-African-American women with at-term deliveries.
The author concluded that higher vaginal levels of β-defensin-2 lowered the risk sPTB associated with cervicovaginal microbiota in an ethnicity-dependent manner. Surprisingly, even in Lactobacillus spp. dominated cervicovaginal microbiota, low β-defensin-2 was associated with increased risk of sPTB. Their findings hold promise for diagnostics to accurately identify women at risk for sPTB early in pregnancy. The study was published on March 21, 2019, in the journal Nature Communications.
Related Links:
University of Maryland School of Medicine
The interaction between microbial communities and their host, in many biological niches, has been found to be mechanistically involved in health and disease pathogenesis. There have been only a few studies that have examined the relationship between cervicovaginal microbial communities and spontaneous preterm birth.
A group of scientists collaborating with the University of Maryland School of Medicine (Baltimore, MD, USA) enrolled within 2,000 pregnant women, and identified a few hundred women for a nested case-control study of spontaneous preterm birth (sPTB), a group that included 107 extensively phenotyped women who gave birth prior to 37 weeks of gestation and 432 unaffected women who delivered their babies at term. Nearly three-quarters of the participants were African-American, and the median age of the mothers was 28 years old. The investigators had access to cervicovaginal swab samples and anthropometric measurements collected at three points during pregnancy: at 16 to 20 weeks gestation, 20 to 24 weeks gestation, and between 24 and 28 weeks gestation.
Amplicons were visualized on a 2% agarose gel, quantified, pooled in equimolar concentration, and purified prior to loading on an Illumina HiSeq 2500 modified to generate 300 bp paired-end reads. When the scientists compared microbial community members in cervicovaginal samples from those cases and controls, which were profiled with 16S ribosomal RNA gene sequencing, they saw seven bacterial taxa that appeared to be associated with spontaneous preterm birth, particularly in women with African-American ancestry. The team studied that association further using enzyme-linked immunosorbent assay (ELISA)-based immunological profiling, focused on host-derived anti-microbial peptides known as beta-defensin-2, that have previously been described in studies of the genital tract, both in healthy women and those suffering from bacterial infections.
The results indicated that the presence of Lactobacillus bacteria that are normally considered beneficial did not necessary coincide with diminished risk of spontaneous preterm birth. Instead, the data suggested that enhanced beta-defensin-2 levels in cervicovaginal samples typically coincided with decreased spontaneous preterm birth risk, while lower-than-usual levels of the protein tended to track with increased risk, even when high levels of bacteria belonging to Lactobacillus species were present. That beta-defensin-2 effect was especially pronounced in the African-American women, but was not significant when the team analyzed data for non-African-American women alone. Likewise, African-American women who delivered their infants at term also had increased beta-defensin-2 levels compared to non-African-American women with at-term deliveries.
The author concluded that higher vaginal levels of β-defensin-2 lowered the risk sPTB associated with cervicovaginal microbiota in an ethnicity-dependent manner. Surprisingly, even in Lactobacillus spp. dominated cervicovaginal microbiota, low β-defensin-2 was associated with increased risk of sPTB. Their findings hold promise for diagnostics to accurately identify women at risk for sPTB early in pregnancy. The study was published on March 21, 2019, in the journal Nature Communications.
Related Links:
University of Maryland School of Medicine
Latest Molecular Diagnostics News
- Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
- Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
- Two-in-One DNA Analysis Improves Diagnostic Accuracy While Saving Time and Costs
- “Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
- New Tool Maps Chromosome Shifts in Cancer Cells to Predict Tumor Evolution
- Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
- Newly-Identified Parkinson’s Biomarkers to Enable Early Diagnosis Via Blood Tests
- New Blood Test Could Detect Pancreatic Cancer at More Treatable Stage
- Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
- New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
- World's First Blood Test Distinguishes Between Benign and Cancerous Lung Nodules
- Rapid Test Uses Mobile Phone to Identify Severe Imported Malaria Within Minutes
- Gut Microbiome Signatures Predict Long-Term Outcomes in Acute Pancreatitis
- Blood Test Promises Faster Answers for Deadly Fungal Infections
- Blood Test Could Detect Infection Exposure History
- Urine-Based MRD Test Tracks Response to Bladder Cancer Surgery
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







